Short Interest in Femasys Inc. (NASDAQ:FEMY) Grows By 24.3%

Femasys Inc. (NASDAQ:FEMY) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 684,700 shares, a growth of 24.3% from the August 31st total of 550,800 shares. Based on an average daily trading volume, of 141,200 shares, the short-interest ratio is presently 4.8 days. Approximately 3.3% of the company’s shares are short sold.

Femasys Stock Performance

Shares of FEMY stock opened at $1.12 on Monday. The stock has a 50-day moving average of $1.09 and a 200-day moving average of $1.23. Femasys has a one year low of $0.73 and a one year high of $4.75. The stock has a market cap of $24.89 million, a PE ratio of -1.33 and a beta of -2.81. The company has a debt-to-equity ratio of 0.43, a current ratio of 6.47 and a quick ratio of 5.93.

Femasys (NASDAQ:FEMY) last issued its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.50 million. Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%. As a group, sell-side analysts expect that Femasys will post -0.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Chardan Capital lowered their target price on shares of Femasys from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Femasys in a research report on Thursday, September 12th.

Institutional Trading of Femasys

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC boosted its stake in shares of Femasys Inc. (NASDAQ:FEMY) by 30.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 309,274 shares of the company’s stock after buying an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned approximately 1.40% of Femasys worth $479,000 as of its most recent filing with the SEC. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.